Abstract
Targeted therapy has become the latest revolution in the management of oral cancer by focusing on the molecular characteristic of the tumor to provide treatment with an accuracy that spares normal healthy tissue. This article discusses current advances in targeted medicine, with focusing on EGFR inhibitors, immune checkpoint inhibitors, and more biomarker-drug-directed therapies. Some of the important advances in enhancing the combination of these therapies with the conventional treatments including surgery, radiation, and chemotherapy are being described here. Furthermore, such features as tailoring medicine for patient needs in order to enhance therapeutic efficacy and counter drug resistance are pointed out as vision with a relatively bright prognosis for increasing survival rates as well as a quality of life of oral cancer patients.